

2nd International Conference on **Hematology & Blood Disorders**

September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

The correlates of novel cardiovascular predictive biomarker: Hyperhomocysteinemia

Mohamad A Ayass and Gul Nowshad
Ayass Lung Clinic & Sleep Center, USA

Introduction: Hyperhomocysteinemia is characterized by abnormally high levels of Homocysteine and are seen in 5% to 12% of the general population. In alcoholics and chronic kidney disease patients, this condition is more common. Elevated Homocysteine irritates the lining of the blood vessels and increased the risk of thrombus formation, by causing them to become scarred, hardened, and fatty. After adjusting for conventional risk factors, Homocysteine level besides three other novel biomarkers, most strongly predicted the risk of death in an analysis from the Framingham Heart Study.

Purpose: The aim of the study was to delineate the factors associated with hyperhomocysteinemia in adult population.

Methods: Four hundred patients seeking health care in a medical clinic were included in the study. For each patient, socio-demographic, laboratory and clinical information about co-morbid conditions (OSA, hypertension and diabetes, cardiac diseases) were obtained. Logistic models with forward selection methods were employed and the outcome variable was Homocysteine > 12 $\mu\text{mol/L}$.

Result: Sixty six patients (16.5%) with hyperhomocysteinemia were mostly older, females, nonsmoker, and obese. However, multivariate analysis indicated that high factor VIII (OR 2.59, $P=0.001$), D-dimer (OR 1.69, $P=0.007$), impaired diffusing capacity of the lung for carbon monoxide DLCO, (OR 2.04, $P=0.017$), were the only determinants of hyperhomocysteinemia after controlling for demographic and comorbid condition.

Conclusions: High factor VIII, high D-dimer's association with hyperhomocysteinemia raises the query that may be these thrombotic risk factors increase the risk of thrombosis through hyperhomocysteinemia. Identification of novel biomarkers for prediction of thromboembolic events will be the hallmark of risk identification, early detection and prevention.

Biography

Mohamad Ammar Ayass received his medical degree (MD) degree from Damascus University College of Medicine in 1988. He received his board certificate in internal medicine in 2001, and his board certificate in pulmonary diseases in 2003. He has been practicing medicine for almost 15 years. He is the founder of Ayass Lung Clinic & Sleep Center, a specialized pulmonary care service organization. He believes in improving quality of care and outcome of patients. He is very passionate about medical discoveries and has published five abstracts regarding lung diseases and sleep disorders. He is a patient advocate and has been actively involved in patient education and community health awareness in Texas.

drgulnowshad@gmail.com